| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.084 | 0.08 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.093 | 0.08 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.077 | 0.09 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.09 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.052 | 0.09 |